Oxford spinout uses nanoparticles to target tough cancers
24th August 2015
A new Oxford spinout is planning to commercialise titania nanoparticles capable of generating cancer-killing free oxygen radicals in tandem with radiotherapy to treat patients with malignant tumours.
Xerion Healthcare, set up with the help of Oxford University Innovation, the University’s technology commercialisation company, has raised £1.5 million from London’s New Wave Ventures and Parkwalk Advisors to continue development and pre-clinical testing of its therapies. Xerion’s technology is based on over seven years of research by Dr Helen Townley at Oxford’s Department of Engineering Sciences
Townley has been investigating how oxygen species generated by the titania nanoparticles can be used to treat cancer tumours. A similar approach is currently used successfully in photodynamic therapy: UV light is used to generate oxygen radicals which kill cancer cells. However, UV light is unable to penetrate into tumours deeper in the body.
Townley and co-inventor Dr Gareth Wakefield found that modified titania nanoparticles generated reactive oxygen species in response to X-ray energy which could penetrate into a tumour deep in the body and kill the cancerous cells.
“The Xerion nanoparticles are completely inert without radiation from radiotherapy,” said Townley. “Essentially we have been able to create a treatment with an ‘on- off- switch’. We can deliver this treatment right at the centre of very dense tumours.
The nanoparticles are just the right size and shape to be taken up by and accumulate in tumour cells. Once inside the tumour they’re likely to stay there, as tumours lack the lymphatic drainage system which removes nanoparticles from the rest of the body.
“Our xenograft studies have shown that this approach can halt the growth of lung cancer tumours which are resistant to standard radiotherapy. We’re planning to run further pre-clinical trials to determine the best dose and regime to take forward into clinical trials.”
Dr Adam Stoten, Head of Technology Transfer (Life Sciences) at Oxford University Innovation, said: “With its nanoparticle treatment, Xerion is initially aiming to help patients with head and neck, and lung cancers. At the moment, these people have poor survival rates because surgery is often not possible and they risk side effects from the toxicity of current treatments.”
Dr Ian George of New Wave Ventures said: “About 40 per cent of cancer patients receive radiotherapy as part of their treatment. Xerion’s inert nanoparticles offer a unique and cost-effective opportunity to enhance radiotherapy treatment for a wide range of cancers. The goal is to reduce X-ray doses and enhance response rates to improve patient care”.
Media enquiries to:
Oxford University Innovation Ltd
T: +44(0)1865 280867
About Oxford University Innovation
Oxford University Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.
Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 503 licenses and consulting agreements. Isis Enterprise, our innovation management consultancy, signed 85 deals with university, government and industrial clients from offices around the world.
Isis was named ‘Technology Transfer Unit of the Year 2014’ by Global University Venturing.
About Parkwalk Advisors
Parkwalk is a London-based independent investment management firm with a portfolio focused on companies spun out from the UK’s leading universities and other research-intensive institutions to develop and commercialise relevant new technology. www.parkwalkadvisors.com
PR158/1Press release sign up